Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1172.12 | -0.4% | 851.2K |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $268.21 | +0.9% | 4.3M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $443.4b | $256.23 | -1.0% | 2.4M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $315.6b | $148.18 | -0.8% | 5.6M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $263.1b | $162.40 | -1.7% | 1.2M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $207.9b | $431.95 | -1.0% | 1.2M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $161.7b | $146.10 | -2.1% | 1.4M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $133.4b | $66.46 | -0.6% | 1.8M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $78.2b | $794.04 | -1.7% | 369.6K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $38.8b | $208.29 | -6.0% | 1.8M |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $38.7b | $329.00 | -3.6% | 306.8K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $25.3b | $60.85 | -1.7% | 1.4M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $24.2b | $123.83 | -2.6% | 579.3K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $22.0b | $137.10 | -3.4% | 5.2M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $21.7b | $162.25 | -4.0% | 1.6M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.9b | $248.70 | -2.6% | 1.1M |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $13.3b | $53.82 | -1.4% | 492.2K |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $12.4b | $113.92 | -2.6% | 364.4K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $9.8b | $105.50 | -1.5% | 1.1M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.5b | $8.08 | -4.2% | 2.4M |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 16.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.7b | $35.16 | -6.5% | 1.5M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $100.70 | +0.3% | 274.6K |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $6.4b | $93.13 | -2.0% | 168.8K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.3b | $18.04 | -7.5% | 2.4M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.3b | $74.28 | -5.9% | 389.2K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $4.4b | $23.43 | -7.6% | 684.4K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.4b | $25.76 | -2.8% | 1.6M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $88.50 | -5.1% | 388.7K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.1b | $19.21 | -3.3% | 2.4M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.8b | $58.25 | -4.4% | 241.6K |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.6b | $43.35 | -4.2% | 605.0K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $3.6b | $25.45 | -4.7% | 558.0K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.5b | $29.21 | -4.5% | 895.8K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.4b | $40.12 | -3.9% | 180.9K |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $2.9b | $79.74 | -3.1% | 559.4K |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.6b | $27.57 | -4.5% | 612.4K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.4b | $26.20 | -2.6% | 618.3K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.4b | $72.44 | -2.7% | 311.8K |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.4b | $7.00 | -3.5% | 2.3M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.2b | $13.45 | -13.4% | 3.5M |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $2.1b | $6.61 | -4.0% | 1.6M |
 NEO | NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.0b | $18.05 | -3.2% | 633.9K |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $2.0b | $15.43 | -3.0% | 1.4M |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $24.98 | -4.3% | 93.8K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | Targeted Therapy & Precision Oncology | $1.9b | $43.59 | -4.2% | 495.4K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.8b | $8.04 | -2.9% | 6.9M |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | Targeted Therapy & Precision Oncology | $1.8b | $29.02 | -5.1% | 285.1K |